XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech announced that its IND application for the V-SPINE Phase II clinical trial evaluating vilamakitug (an IL-1α antibody) for treating active axial spondyloarthritis has completed FDA review without a clinical hold. The double-blind, placebo-controlled study will enroll 150 participants and evaluate the drug's efficacy and safety, with the primary endpoint being ASAS40 response at Week 16.